Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
First-Quarter 2023 Results: -- Net Sales of $832.1 Million -- -- GAAP Net Income of $54.7 Million; Adjusted EBITDA of $232.9 Million -- -- TEPEZZA® Net Sales of $405.3 Million -- --... | May 3, 2023
Source: marketscreener.com